TrialSignal transduction and targeted therapy2024

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.

Zhiyong Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.